Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure

Nephrology Dialysis Transplantation

Volumn 12, Issue 2, 1997, Pages 255-258

  Miyata, T ^a   Maeda, K ^a   Kurokawa, K ^b   Van Ypersele De Strihou, C ^c  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKAI UNIVERSITY   (Japan)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Advanced glycation end products; Glycoxidative stress; Pentosidine; Redox; Uraemic complication

Indexed keywords

ALDEHYDE; BETA 2 MICROGLOBULIN; MATRIX PROTEIN; REACTIVE OXYGEN METABOLITE;

AMYLOIDOSIS; ARTICLE; BLOOD VESSEL INJURY; DIABETES MELLITUS; DYSLIPIDEMIA; GLYCATION; HYPERGLYCEMIA; KIDNEY FAILURE; OXIDATION; PRIORITY JOURNAL; TISSUE INJURY; UREMIA;

GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; OXIDATION-REDUCTION; OXIDATIVE STRESS; UREMIA;

EID: 0031040243     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/12.2.255     Document Type: Article

References (35)

1. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-1321
2. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267: 14998-15004
3. Schmidt AM, Yon SD, Brett J, Mora R, Nowygrod R, Stern D. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 1993; 92: 2155-2168
4. Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR, Baynes JW. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993; 91: 2463-2469
5. Sell DR, Lapolla A, Odetti P, Forgarty J, Monnier VM. Pentosidine formation in skin correlates with severity of complication in individuals with long standing IDDM. Diabetes 1992; 41: 1286-1292
6. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thrope SR, Baynes JW, Lyons TJ. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 1993; 91: 2470-2478
7. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629-1632
8. Odetti P, Forgarty J, Sell DR, Monnier VM. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 1992; 41: 153-159
9. Miyata T, Ueda Y, Shinzato T, Iida Y, Tanaka S, Kurokawa K, van Yperesele de Strihou C, Maeda K. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 1996; 7: 1198-1206
10. 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993; 92: 1243-1252
11. 2-microglobulin in patients with hemodialysis-associated amyloidosis: identification of the glycated sites. Biochemistry 1994; 33: 12 215-12 221
12. 2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci USA 1996; 93: 2353-2358
13. 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis: induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-α and interleukin 1. J Clin Invest 1994; 93: 521-528
14. 2-Microglobulin modified with advanced glycation end products induces interleukin-6 from human macrophages. Role in the pathogenesis of hemodialysis-associated amyloidosis. Biochem Biophys Res Commun 1994; 201: 1235-1241
15. 2-microglobulin modified with the advanced glycation end products. Kidney Int 1996; 49: 538-550
16. 2-microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: implication for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 1996; 98: 1088-1094
17. Miyata T, Notoya K, Yoshida K, Hone K, Kurokawa K, Maeda K, Taketomi S. Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Neprol (in press)
18. Sell DR, Monnier VM. Structure elucidation of a senescence cross-link from human extracellular matrix. J Biol Chem 1989; 264: 21 597-21 602
19. E-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986; 261: 4889-4894
20. 2-microglobulin forming amyloid fibrils in patients with dialysis-related amyloidosis. J Amer Soc Neprol 1995; 6: 552
21. Baynes JW. Perspectives in diabetes: Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-412
22. Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW. Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 1995; 34: 3702-3709
23. Wells-Knecht MA, Thorpe SR, Baynes JW. Pathways of formation of glycoxidation products during glycation of collagen. Biochemistry 1995; 34: 15 134-15 141
24. Glomb MA, Monnier VM. Mechanism of protein modification by glyoxal and glycoaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 1995; 270: 10017-10026
25. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW. Formation of pentosidine during nonenzymatic browning of protein by glucose: identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 1991; 266: 11 654-11 660
26. E-(carboxymethyl) lysine by reaction between lysine and products of autoxidation of ascorbate. Biochemistry 1990; 29: 10 964-10 970
27. Grandhee SK, Monnier VM. Mechanism of formation of the Maillard protein cross-link pentosidine. J Biol Chem 1991; 266: 11 649-11 653
28. Loughrey CM, Young IS, Kightbody JH, McMaster D, McNamee PT, Trimble ER. Oxidative stress in haemodialysis. Q J Med 1994; 87: 679-683
29. Peuchant E, Carbonneau MA, Dubourg L, Thomas MJ, Perromat A, Vallot C, Clerc M. Lipoperoxidation in plasma and red blood cells of patients undergoing haemodialysis: vitamins A, E, and iron status. Free Radical Biol Med 1994; 16: 339-346
30. Canestrari F, Galli F, Giorgini A, Albertini MC, Galiotta P, Pascucci M, Bossu M. Erythrocyte redox state in uremic anemia: effects of hemodialysis and relevance of glutathione metabolism. Acta Haematol 1994; 91: 187-193
31. Yeung JH. Effects of glycerol-induced acute renal failure on tissue glutathione and glutathione-dependent enzymes in the rat. Meth Find Exp Clin Pharmacol 1991; 13: 23-28
32. Kumano K, Yokota S, Go M, Suyama K, Sakai T, Era S, Sogami M. Quantitative and qualitative changes of serum albumin in CAPD patients. Adv Perit Dial 1992; 8: 127-130
33. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-1313
34. Friedlander MA, Witko-Sarsat V, Nguyen AT, Wu CY, Labrunie M, Verger C, Jungers P, Descamps-Latscha B. The advanced glycation endproduct pentosidine and monocyte activation in uremia. Clin Nephrol 1996; 45: 379-382
35. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Maeda K, Kurokawa K, van Ypersele de Strihou C. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int (in press)